In nature, the riparian zone is a unique rich ecosystem created through the interaction of a river with its banks. In the human body, moving blood, or hemodynamics, similarly interacts with the walls of blood vessels generating unique biological activity. This very interaction, between hemodynamics and the vascular wall, is a critical and unexplored determinant of vascular health. Riparian is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today.
WILL ADAMS, PHD
Chief Scientific Officer, President, Founder
Prior to founding Riparian Pharmaceuticals, Will performed his dissertation research at Brigham and Women's Hospital and Harvard Medical School where he developed stem cell based platforms for drug discovery and personalized regenerative medicine. Will received a Ph.D. in Biomedical Engineering, a M.S. in Applied Mathematics and a B.S. in Biomedical Engineering from Harvard University.
virginia guarani-pereira, PHD
Virginia is an expert in vascular cell biology, cell signaling and proteomics. She received her Ph.D. from Frankfurt University studying endothelial biology with Dr. Stefanie Dimmeler. Her postdoctoral research studied macromolecular cellular signaling complexes using a systematic high-throughput proteomic framework with Wade Harper at Harvard Medical School. Among others, an important finding of her work is the discovery the molecular mechanism responsible for a rare metabolic disease.
GUILLERMO GARCIA-CARDENA, PHD
Founder, Scientific Advisor
Guillermo is an Associate Professor of Pathology at Harvard Medical School and the Director of the Laboratory for Systems Biology at the Center for Excellence in Vascular Biology at Brigham and Women’s Hospital in Boston. His expertise in the endothelial biology of cardiovascular diseases is widely recognized as this has been a focus of his laboratory for the past fifteen years.
He received his Ph.D. from Yale University working with William C. Sessa on the molecular regulation of nitric oxide production in vascular endothelium. His postdoctoral research with Michael A. Gimbrone Jr. at Harvard Medical School studied endothelial cell gene expression, hemodynamics, and atherogenesis. He authored 78 scientific publications primarily focused on vascular biology.
ron wester, phD
Ron has more than 25 years of leadership experience in the pharmaceutical industry. Most recently, Ron was the founding chemist at Nimbus Therapeutics after a medicinal chemistry career at Pfizer, where he discovered or co-discovered numerous clinical and preclinical candidates including Phase 3 CETP inhibitor torcetrapib (HDL-cholesterol elevation), Phase 2 NHE-1 inhibitor zoniporide (cardioprotection) and Phase 2 renin inhibitor terlakiren (blood pressure reduction). As Executive Director of Cardiovascular & Metabolic Diseases Medicinal Chemistry, Ron led more than 100 chemists, and was responsible for establishing and advancing a diverse portfolio of projects across six therapeutic areas (atherosclerosis, cardiovascular, diabetes, obesity, osteoporosis and frailty). He chaired the CETP Early Clinical Management Team, overcoming numerous development challenges while advancing torcetrapib through preclinical and Phase 1 studies. As Vice President of Exploratory Medicinal Sciences, Ron led up to 325 scientists in providing Pfizer drug discovery projects with integrated technology support, including new lead identification, computational sciences, analytical chemistry, reagent provision, biomarker and functional genomics, and exploratory safety.
He earned his Ph.D. in synthetic organic chemistry from Yale University with Professor Fred Ziegler. Ron authored or co-authored 26 scientific publications and presentations, and is an inventor on 15 issued U.S. patents.